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Middle East Respiratory Syndrome Coronavirus 
A B S T R A C T   
Introduction: The emergence of the Severe Acute Respiratory Syndrome Coroanvirus 2 (SARS-CoV-2) had raised 
possibilities of coinfection with the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in countries 
were these two viruses were reported. In this study, we describe the clinical presentation and demographics of 
eight patients who were coinfected with SARS-CoV-2 and MERS-CoV. 
Materials and methods: This is a case series of hospitalized patients admitted to intensive care units (ICUs). We 
collected demographics, underlying conditions, presenting symptoms and clinical outcome from the patients’ 
medical records. 
Results: During the study period from March 14, 2020 to October 19, 2020, there was a total of 67 SARS-CoV-2 
ICU admitted patients who underwent simultaneous SARS-CoV-2 and MERS-CoV testing by PCR. Of those pa-
tients, 8 (12%) tested positive for both SARS-CoV-2 and MERS-CoV. There were 6 (75%) males, the mean age ±
SD was 44.4 ± 11.8 years, and 7 (87.5%) were obese. Of the patients, 7 (87.5%) were non-smokers, 1 (12.5%) 
had diabetes mellitus, 1 (12.5%) had heart failure, and 1 (12.5%) had been on anti-platelet therapy. The mean 
hospital length of stay (LOS) was 21.1 ± 11.6 days and the average ICU LOS was 10.9 ± 6.03 days. All patients 
received supportive therapy and all were treated with corticosteroid. Of all the patients, 4 (50%) were discharged 
home and 3 (37.5%) died. 
Conclusion: This case series is an important addition to the medical knowledge as it showed the interaction of the 
coinfection of SARS-CoV-2 and MERS-CoV.   
1. Introduction 
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV- 
2) emerged at the end of 2019 and had caused the current CoronaVirus 
Disease 19 (COVID-19) pandemic. COVID-19 had been associated with 
tremendous medical challenges as well as societal and industrial 
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interruption [1]. COVID-19 clinical presentation ranges from asymp-
tomatic to severe disease [2–6]. And the case fatality rate of COVID-19 is 
variable [7,8]. The clinical characteristics of the disease in Saudi Arabia 
is similar to other reported presentations [4–6,8,9]. 
Recently, there had been few reports of coinfection of different 
micro-organisms with SARS-CoV-2. Coinfections with SARS-CoV-2 were 
reported with influenza, other respiratory pathogens, herpes simplex 
virus (HSV) and human immune deficiency virus (HIV) [10–15]. In the 
Kingdom of Saudi Arabia (KSA), the Middle East Respiratory Syndrome 
Coronavirus (MERS-CoV) is of particular concern as KSA is the country 
where MERS-CoV had been initially identified in 2012 [16–18]. One 
particular characteristic of MERS-CoV is the ability to cause healthcare 
associated outbreaks [19–21]. 
In addition, MERS-CoV is of particular importance as it has about 
35% case fatality rate [22]. 
The first case of COVID-19 was reported in Saudi Arabia on March 
2nd, 2020 [6,9]. However, we are not aware of any reports of coinfec-
tion of SARS-CoV-2 and MERS-CoV. In an initial cohort of 99 patients of 
SARS-CoV-2, none of them had coinfection with MERS-CoV [23]. Here, 
we describe the clinical and demographics of patients who were coin-
fected with SARS-CoV-2 and MERS-CoV. 
2. Materials and methods 
This is a case series of hospitalized patients admitted to intensive 
care units (ICUs) from March 14, 2020 to October 19, 2020. We 
collected demographics, underlying conditions, presenting symptoms 
and clinical outcome from the patients’ medical records. Nasopharyn-
geal swabs were tested for the presence of MERS-CoV upE and orf1a [24, 
25] and for SARS-CoV-2 E and S genes using the RealStar® SARS-CoV-2 
real-time Reverse Transcriptase PCR (RT-PCR) as described previously 
[6,23,26]. The study was approved by the IRB of the Central IRB of 
Ministry of Health (Log No: 20-80E). 
3. Results 
3.1. Case summaries 
During the study period, there was a total of 67 SARS-CoV-2 patients 
who were admitted to the ICUs and underwent simultaneous SARS-CoV- 
2 and MERS-CoV testing by PCR at the discretion of the treating phy-
sicians. Of those patients, 8 (12%) tested positive for both SARS-CoV-2 
and MERS-CoV. 
3.2. Demographics and clinical characteristics 
Of the eight patients, there were 6 (75%) males. The mean age ±SD 
was 44.4 ± 11.8 years and the mean Body Mass Index (BMI) was 31 ±
4.7. Based on BMI, 1 (12.5%) had normal BMI and 7 (87.5%) were obese 
and of these 2 (25%) were overweight (BMI 25–29.9), 3 (36.5%) were 
obese (BMI: 30–34.9), and 2 (25%) had extreme obesity (BMI: > 35) 
(Table 1). 
One patient (12.5%) was Saudi and 1 (12.5%) was a healthcare 
worker. Of the patients, 7 (87.5%) were non-smokers, 1 (12.5%) had 
diabetes mellitus, 1 (12.5%) had heart failure, and 1 (12.5%) had anti- 
platelet therapy. None of the patients had hypertension, ischemic heart 
disease, chronic obstructive pulmonary disease (COPD), asthma, liver 
disease; hemoglobinopathy; chronic kidney disease (CKD); renal 
Table 1 
Characteristics, clinical presentation and outcome of ICU MERS-CoV and SARS-CoV-2 coinfected patients.  
Patient Number 1 2 3 4 5 6 7 8 
ICU LOS (days) 18 7 12 21 8 3 11 7 
Hospital LOS (days) 18 19 39 31 29 4 20 9 
Age (years) 48 36 36 39 33 52 69 42 
Gender Male male male female male male female male 
Was patient Saudi or non-Saudi? non-Saudi non-Saudi non-Saudi non-Saudi non-Saudi non-Saudi non- 
Saudi 
Saudi 
BMI 32.8 38.1 31.9 23.9 29.0 31.1 35.2 26.0 
Was the case in close contact with a person with fever and/or 











No No Yes 
Current smoker No no no no unknown no no no 
Diabetes mellitus No no no no no no yes no 
Hypertension no no no no no no no no 
Ischemic heart disease no no no no no no no no 
Heart failure (ejection fraction < 50%) no no no no no no yes no 
Chronic Lung disease no no no no unknown no no no 
Duration of symptoms prior to hospital admission 1 4 4 2 2 asymptomatic 4 4 
Shortness of breath (Dyspnoea) yes yes yes yes yes yes yes yes 
Runny nose (rhinorrhoea) yes unknown no no unknown no yes no 
Gastrointestinal symptoms (Diarrhea/vomiting) yes unknown no no unknown yes yes yes 
History of fever yes yes yes yes yes yes no yes 
Altered consciousness/confusion no unknown no no unknown no no yes 
Cough yes yes yes yes yes yes no yes 
Hospital Admission Mean BP (mmHg) 101 85  73 129 82 109 91 
Heart rate (beats/minute) 86 85  103 110 104 96 90 
Respiratory rate (breaths/minute) 32 22  24 20 20 25 17 
Oxygen saturation (on room air) (%) 75 81  88 96 88 94 98 
Temperature (highest within the first 24 h) (◦C) 38 38.3  38.1 39 39.6 37.2 38.6 
Glasgow Coma Score (GCS) 15 15  15 10 15 15 15 
Chest X-ray - Consolidation yes no yes yes yes no no yes 
CXR infiltrate on admission bilateral no bilateral bilateral bilateral no no bilateral 
ICU admission PH value 7.28 7.415 7.37 7.44 7.411  7.49  
PCO2 value (mmHg) 55.9 41.1 36.1 39.9 36.6  51  
PaO2 value (mmHg) 95.9 61.8 207 60 89  71  
O2 Saturation (%) 96.6 91.7 99.8 93 97.7  99 91 
Intubated and mechanically ventilated yes yes yes yes yes yes yes no 
Hospital discharge outcome death home death home home transferred 
out 
death home 
ICU: intensive care unit; LOS: length of stay; BMI: body mass index; CXR: chest x-ray. 
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replacement; immunocompromised; transplant; malignancy; or recent 
surgery. 
3.3. Symptoms 
All patients had shortness of breath, 2 (25%) had runny nose, 4 
(50%) had gastrointestinal (GI) symptoms, and 7 (87.5%) had history of 
fever. Altered consciousness/confusion was present in 1 (12.5%), cough 
in 7 (87.5%), abdominal pain in 6 (75%), headache in 1 (12.5%), chest 
pain in 1 (12.5%), arthralgia, myalgia, and fatigue each was present in 
12.5%, and sore throat in 3 (37.5%). 
3.4. Hospital course 
The initial mean and SD of laboratory tests are shown in Table 2. The 
mean hospital length of stay (LOS) was 21.1 ± 11.6 days, the average 
ICU LOS was 10.9 ± 6.03 days. The initial mode of oxygen delivery was 
face mask (1; 12.5%), non-rebreather mask (NRM) (4; 50%), and me-
chanical ventilation (3; 37.5%). However, eventually 7 (87.5%) 
required mechanical ventilation and the average duration of mechanical 
ventilation was 6.67 (±5.9) days. All patients received supportive 
therapy and all were treated with corticosteroid. The patients did not 
recieve specific anti-viral therapy. Of all the patients, 1 (12.5%) was 
transferred to another facility, 4 (50%) were discharged home and 3 
(37.5%) died. 
4. Discussion 
This case series is a unique contribution to the medical literature by 
examining coinfection of two emerging respiratory pathogens, MERS- 
CoV and SARS-CoV-2. These two viruses had the chance to cause sig-
nificant disease in the Kingdom of Saudi Arabia. The country had gained 
great experience from previous MERS-CoV infection and had adopted a 
significant infection control and preventative measures [27]. Coinfec-
tion of SARS-CoV-2 and other respiratory viruses had been reported 
[10–15]. In addition, there few cases of coinfection of MERS-CoV and 
influenza or tuberculosis [28,29]. Here, we report coinfection of 
MERS-CoV and SARS-CoV-2 in admited patients. In an initial cohort of 
99 cases who were tested simultaneously for MERS-CoV and 
SARS-CoV-2, none of them had SARS-CoV-2 and MERS-CoV coinfection 
[23]. In the current study, 12% of the tested patients were positive for 
both SARS-CoV-2 and MERS-CoV. It was reported that in the past few 
years, MERS-CoV positivity rates among suspected cases was 2–6% [30]. 
The difference in these two estimates is likely related to the population 
of patients being tested. 
The included patients were relatively young with a mean age ±SD of 
44.4 ± 11.8 years. Previously, the mean age of COVID-19 patients in 
Saudi Arabia was 36–50 years [6,31] and a median age 44 years [23]. 
The presence of comorbidities in patients with SARS-CoV-2 ranges from 
32% to 93% in different studies [32–34]. One half of the included pa-
tients had gastrointestinal symptoms. Previously, gastrointestinal 
symptoms were reported in 33% of MERS-CoV patients [24,25,35–38], 
and 29% of COVID-19 patients had gastrointestinal symptoms [39] and 
another study showed higher rate of diarrhea in elderly patients [40]. In 
addition, the majority of hospitalized MERS-CoV patients had fever, 
cough and shortness of breath in addition to pneumonia on chest x-ray 
[24,25,35,41]. 
This case series showed that 37.5% of ICU coinfected patients had 
died. Previous studies of MERS-CoV showed a case fatality rate of 30% 
with increasing rate among those with comorbidities [24], critical ill 
patients, severe disease, those > 65 years of age, hospital-acquired in-
fections and corticosteroid use [35,42–48]. However, the use of corti-
costeroid was associated with decreased case fatality rate in randomized 
controlled trials of COVID-19 patients from 25.7% in standard therapy 
to 22.9% in the dexamethasone group [49]. In addition, there is a 
variation in the case fatality rates among different countries and 
different time intervals and ranged from 60% in March 2020 to 42% in 
May 2020 [50]. The epidemiology of MERS-CoV infection is Saudi 
Arabia is well characterized by sporadic cases from camel exposure 
followed by either hospital [19–21] or community transmission 
[51–53]. However, we were not able to pinpoint the exact exposure of 
infection of the included patients. 
The initial laboratory findings of the included patients showed 
normal WBC and lymphocyte counts. However, the mean ± SD of the 
neutrophils to lymphocyte count ratio (NLCR) was 10.14 (8.77). The 
NLCR of ≥3.13 is a predictor of ICU admission and a marker of disease 
severity [32]. A previous study from Saudi Arabia showed that NLCR 
was significantly higher among ICU admissions than other patients [6]. 
We did not examine the duration of viral shedding in this study. A 
previous meta-analysis showed that the mean shedding duration of 
MERS-CoV was 15⋅3 days in the upper respiratory tract and 16⋅3 days in 
the lower respiratory tract. On the other hand, in COVID-19 patients the 
shedding of SARS-CoV-2 had a mean duration of 17 days in upper res-
piratory tract and 14⋅6 days in lower respiratory tract [54]. It was stated 
that SARS-CoV-2 viral loads peak about 10 days after symptoms onset 
[55,56]. 
In conclusion, this case series is important as it showed the interac-
tion of the coinfection of SARS-CoV-2 and MERS-CoV. However, in this 
small case-series the combined infection was not associated with 
increased risk of death in comparison with mono-infection with MERS- 
CoV. However, as there was one patient who is transferred to another 
facility and lost to follow-up and if that patient died then the mortality 
would be 50%. Thus, additional studies are required to confirm or refute 
this finding and it is not possible to draw a firm conclusion about the 
mortality in co-infected MERS-CoV and SARS-CoV-2 patients. The pre-
senting symptoms and laboratory data are not different from each of the 
infection alone. Although, 7 (87.5%) of the coinfection of MERS-CoV 
and SARS-CoV-2 were in the ICU, this is related to the fact that all 
tested and included patients were ICU patients. Thus, a firm conclusion 
could not be drawn in regard to the epidemiology, clinical presentation 
and outcome of this type of coinfection. With the continued COVID-19 
pandemic, there is a continued need to continue precautionary mea-
sures including social distancing, hand hygiene and universal masking. 
These measures continued to be enforced in the Kingdom of Saudi 
Arabia [9,57]. Moreover, KSA implemented universal masking in public 
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